Physician profile
James Smith
NPI 1023007812
$2,056.13
in general payments reported to CMS, 2019-2025
21 companies · $209 in 2025
The $209 reported for 2025 was more than what 77% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $548 · 2020: $278 · 2021: $81.15 · 2022: $251 · 2023: $478 · 2024: $211 · 2025: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $899.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $898.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $580.64 | 2019-2024 | Xarelto |
| Pfizer INC. | $384.85 | 2019-2025 | |
| Abiomed | $273.18 | 2023-2025 | Impella |
| Ethicon US, LLC | $184.55 | 2019-2024 | Echelon Endopath, Echelon; Endopath |
| Allergan, INC. | $134.89 | 2019 | |
| Merck Sharp & Dohme LLC | $97.36 | 2019-2025 | Zerbaxa, Recarbrio, Dificid |
| Shockwave Medical, INC | $75.19 | 2025 | |
| Medtronic USA, INC. | $60.53 | 2020 | |
| Shire North American Group INC | $39.63 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.83 | 2020-2021 | |
| Portola Pharmaceuticals, LLC | $21.27 | 2020 | |
| Philips North America LLC | $19.77 | 2024 | (P88) Igt Devices Fm |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.72 | 2022 | |
| Ethicon INC. | $17.98 | 2025 | Monarch Platform |
| Chiesi USA, INC. | $17.30 | 2025 | Kengreal, Cleviprex |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $16.93 | 2021 | |
| Novartis Pharmaceuticals Corporation | $16.65 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $16.45 | 2019 | |
| Insmed, INC. | $16.24 | 2020 | |
| La Jolla Pharmaceutical Company | $14.61 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $12.56 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.